DelveInsight’s “Psoriasis Pipeline Insight, 2025” report provides comprehensive insights about 65+ companies and 75+ pipeline drugs in the Psoriasis pipeline landscape. It covers the Psoriasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Psoriasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Psoriasis Research. Learn more about our innovative pipeline today! @ Psoriasis Pipeline Outlook
Key Takeaways from the Psoriasis Pipeline Report
Stay informed about the cutting-edge advancements in Psoriasis treatments. Download for updates and be a part of the revolution in Immunological and Autoimmune Disorders care @ Psoriasis Clinical Trials Assessment
Psoriasis Emerging Drugs Profile
Piclidenoson, generically known as IB-MECA (methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl]-b-D-ribofuronamide), is an oral small molecule drug formulated in a tablet. Piclidenoson mechanism of action is A3AR mediated and includes modulation of key signaling proteins, such as PI3K, PKA, PKB/Akt, IKK and NF-kB, resulting in de-regulation of the Wnt/β-catenin pathway and inhibition of inflammatory cytokine production. Currently, the drug is in Phase III stage of its development for the treatment of Psoriasis.
Sonelokimab is an investigational Nanobody® developed by MoonLake Immunotherapeutics for treating inflammatory diseases. It targets IL-17A and IL-17F cytokines, inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers, and includes a domain that binds to human albumin to enhance tissue penetration . In Phase 2 trials, sonelokimab demonstrated superior efficacy compared to AbbVie’s Humira in psoriatic arthritis, with higher percentages of patients achieving significant improvements in joint swelling and psoriasis severity . Additionally, it showed promising results in treating hidradenitis suppurativa, meeting the HiSCR75 endpoint in the Phase 2 MIRA trial. Currently, MoonLake is conducting Phase III trials for both conditions and exploring its use in other inflammatory diseases such as palmoplantar pustulosis and axial spondyloarthritis.
QY101 is a topical ointment developed by E-nitiate Biopharmaceuticals for treating inflammatory skin conditions like atopic dermatitis and plaque psoriasis. It functions as a non-steroidal, non-hormonal phosphodiesterase 4 (PDE4) inhibitor, aiming to reduce inflammation by targeting overactive PDE4 pathways. Preclinical studies have demonstrated favorable pharmacokinetics, strong efficacy, and high safety, making it suitable for various age groups, including children. Currently, QY101 is undergoing a Phase II clinical trial in China for plaque psoriasis, following the completion of a Phase I trial in healthy volunteers. The company is also exploring additional formulations, such as an inhaler, through licensing collaborations.
SFA-002, an IL-10 up-regulator in immune cells, is approaching Phase 2 clinical trials and has shown promising Phase 1a and Phase Ib results for the treatment of psoriasis. SFA-002 met its primary endpoint of safety in the Phase 1b clinical trial. No treatment related adverse events or toxicities were observed during the treatment period, and no rebound effects were observed. SFA Therapeutics has filed its annual safety update with the U.S. Food and Drug Administration. SFA-002 met its exploratory endpoint of efficacy. Patients administered SFA-002 demonstrated statistically significant Psoriasis Area and Severity Index (PASI) percentage change and Investigator Global Assessment (IGA) score improvements compared to placebo. PASI is a tool used to measure the severity and extent of psoriasis while IGA is a standardized rating system of patient disease severity. The study was designed in two cohorts, to evaluate two different formulations. Currently the drug is in Phase II/III stage of its development for the treatment of Psoriasis.
RLS-1496 is a first-in-class GPX4 modulator that targets aging cells and surrounding tissues being developed by Rubedo Life Sciences for the treatment of dermatological conditions and other chronic age-related diseases. It is a topical medicine designed to target aging cells, specifically senescent cells, in skin lesions of chronic atopic dermatitis and chronic psoriasis. Currently the drug is in Preclinical stage of its development for the treatment of Psoriasis.
The Psoriasis Pipeline Report provides insights into
Learn more about Psoriasis Drugs opportunities in our groundbreaking Psoriasis research and development projects @ Psoriasis Unmet Needs
Psoriasis Companies
Can-Fite Biopharma, Huabo Biopharm Co., Ltd., MoonLake Immunotherapeutics, E-nitiate Biopharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, BioRay Pharmaceutical Co., Ltd., SFA Therapeutics, Rubedo Life Sciences, Inc. and others.
Psoriasis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Psoriasis Products have been categorized under various Molecule types such as
Discover the latest advancements in Psoriasis treatment by visiting our website. Stay informed about how we’re transforming the future of Immunological and Autoimmune Disorders @ Psoriasis Market Drivers and Barriers, and Future Perspectives
Scope of the Psoriasis Pipeline Report
For a detailed overview of our latest research findings and future plans, read the full details of Psoriasis Pipeline on our website @ Psoriasis Emerging Drugs and Companies
Table of Contents
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/report-store/psoriasis-pipeline-insight